GAITHERSBURG, Md.--(BUSINESS WIRE)--Calibrant Biosystems announced today that the company has signed a Cooperative Research and Development Agreement (CRADA) with the Armed Forces Institute of Pathology (AFIP) to explore the use of Calibrant’s novel Gemini(TM) proteomics technology in the discovery and development of novel protein biomarkers. The AFIP is an agency of the United States Department of Defense, whose mission is consultation, education and research.
